PRESS RELEASE published on 06/13/2025 at 07:30, 1 year 3 months ago Inside Information / Other news releases MaaT Pharma presents updated positive data for Xervyteg® in treating acute Graft-versus-Host Disease at EHA Congress, validating high efficacy observed in pivotal ARES study MaaT Pharma Acute Graft-versus-Host Disease EMA Approval Xervyteg EAP Data
PRESS RELEASE published on 06/13/2025 at 07:30, 1 year 3 months ago Informations privilégiées / Autres communiqués MaaT Pharma présente des données actualisées positives pour Xervyteg® lors du Congrès de l’EHA confirmant une forte efficacité observée dans l’étude pivotale ARES dans la maladie aiguë du greffon contre l’hôte Thérapie MaaT Pharma AGvH Xervyteg EHA
BRIEF published on 05/12/2025 at 07:35, 1 year 4 months ago Données prometteuses pour MaaT033 dans la SLA Microbiome Sclérose Latérale Amyotrophique MaaT033 Sécurité Et Tolérabilité Essai Clinique Phase 1b
BRIEF published on 05/12/2025 at 07:35, 1 year 4 months ago Promising data for MaaT033 in ALS Microbiome Amyotrophic Lateral Sclerosis MaaT033 Safety And Tolerability Phase 1b Clinical Trial
PRESS RELEASE published on 05/12/2025 at 07:30, 1 year 4 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce des données finales prometteuses pour son essai de Phase 1b évaluant MaaT033 dans la Sclérose Latérale Amyotrophique (SLA). Résultats encourageants et implications thérapeutiques importantes Microbiome Ecosystem Therapies MaaT Pharma Sclérose Latérale Amyotrophique Phase 1b Modulation Du Microbiote
BRIEF published on 04/08/2025 at 07:35, 1 year 5 months ago MaaT Pharma Announces Positive Interim Safety Results for MaaT033 Phase 2B Trial MaaT Pharma MaaT033 Allo-HSCT DSM Safety
BRIEF published on 04/08/2025 at 07:35, 1 year 5 months ago MaaT Pharma annonce des résultats intermédiaires positifs concernant l'innocuité du MaaT033 MaaT Pharma Essai De Phase 2b MaaT033 Allo-GCSH Sécurité DSM
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 5 months ago Inside Information / Other news releases MaaT Pharma announces positive safety interim analysis from DSMB for Phase 2b trial evaluating MaaT033 for patients receiving Allo-HSCT, demonstrating favorable safety profile and tolerability Phase 2B Trial MaaT Pharma Safety Analysis MaaT033 Allo-HSCT
PRESS RELEASE published on 04/08/2025 at 07:30, 1 year 5 months ago Informations privilégiées / Autres communiqués MaaT Pharma annonce résultat positif analyse intermédiaire sécurité essai clinique Phase 2b MaaT033 allo-GCSH. DSMB recommande poursuite essai sans modification Sécurité DSMB MaaT Pharma Analyse Intermédiaire Allo-GCSH
BRIEF published on 04/07/2025 at 07:35, 1 year 5 months ago MaaT Pharma : Nouvelle couverture par H.C. Wainwright & Co Cancer Cotation Euronext Microbiome Ecosystem Therapies MaaT Pharma H.C. Wainwright & Co
Published on 10/01/2026 at 01:21, 5 hours 1 minute ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 5 hours 22 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 6 hours 52 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 9 hours 47 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 09/30/2026 at 15:50, 14 hours 32 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 10/01/2026 at 05:05, 1 hour 16 minutes ago Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
Published on 09/30/2026 at 23:23, 6 hours 58 minutes ago LM PAY S.A. publishes audited FY 2025 results: EBIT reaches PLN 12.4 million and exceeds preliminary result and guidance
Published on 09/30/2026 at 22:34, 7 hours 47 minutes ago The Change of Date of the Annual Report 2025 Publication
Published on 09/30/2026 at 22:05, 8 hours 16 minutes ago ADS-TEC Energy Reports First Half 2026 Results; Advances Gigawatt-Scale SKM Storage Project and Strengthens its Position to Scale Own & Operate Model
Published on 09/30/2026 at 22:05, 8 hours 16 minutes ago Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Published on 09/30/2026 at 18:44, 11 hours 37 minutes ago Broadcast of the 5th edition of “On the way up”
Published on 09/30/2026 at 18:44, 11 hours 37 minutes ago Diffusion de la 5e édition de “On the way up”
Published on 09/30/2026 at 18:18, 12 hours 3 minutes ago Nombre total de droits de vote et d'actions composant le capital social
Published on 09/30/2026 at 18:15, 12 hours 6 minutes ago The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026
Published on 09/30/2026 at 18:15, 12 hours 6 minutes ago L’État belge et le groupe ENGIE ont convenu de reporter au 4 novembre 2026 la date cible pour la conclusion des Heads of Terms
